AI Slashes Colorectal Cancer Diagnosis from Weeks to Minutes

By Charles Rivera

CAMBRIDGE, UK – January 29, 2026 – A groundbreaking artificial intelligence platform is set to radically accelerate colorectal cancer care, reducing the agonizing wait for critical diagnostic results from several weeks to mere minutes. A landmark clinical study published in the prestigious journal npj Digital Medicine has validated an AI software that can accurately identify key molecular biomarkers for colorectal cancer directly from routine tissue images, heralding a new era of rapid, accessible precision medicine.

The software, PANProfiler Colorectal (MSI/MMR), developed by the Cambridge-based company Panakeia, has demonstrated the ability to bypass the slow and resource-intensive laboratory testing that has long been a bottleneck in the cancer care pathway. For patients and clinicians, this breakthrough promises to enable faster treatment decisions, reduce anxiety, and alleviate strain on overburdened healthcare systems.

A Paradigm Shift in Diagnostic Speed

The current standard of care for newly diagnosed colorectal cancer patients involves molecular profiling to check for microsatellite instability (MSI) or mismatch repair deficiency (MMR). These biomarkers are crucial; they determine a patient's eligibility for highly effective immunotherapies, provide prognostic information, and can even reveal a hereditary risk for cancer through conditions like Lynch syndrome. Traditionally, this testing requires complex, multi-step laboratory procedures like immunohistochemistry (IHC) or polymerase chain reaction (PCR), with results often taking weeks to return.

Panakeia's technology upends this timeline. The AI analyzes routine hematoxylin and eosin (H&E) stained tissue slides—the most common type of slide prepared for cancer diagnosis—and delivers the MSI/MMR status digitally within minutes. This requires no additional wet-lab tests or changes to a hospital's existing diagnostic workflow.

The validation study, the largest of its kind, was led by the University of Leeds and Leeds Teaching Hospitals NHS Trust and conducted across three independent UK institutions. It involved a rigorous, blinded evaluation of 3,576 images from 1,243 patients, designed to mimic real-world clinical variability.

The results were striking. The software achieved an overall agreement of 93.83% with the gold-standard laboratory tests. Critically, it successfully returned a definitive result in 86.55% of cases, the highest test replacement rate demonstrated to date by any AI solution for molecular profiling from tissue images. This high rate of applicability is a significant scientific breakthrough, proving the tool is not just accurate but broadly usable.

Dr. Nic Orsi, a lead researcher from St James's University Hospital, commented on the study's rigor: "This study was designed to rigorously and independently assess whether AI-based MSI/MMR testing can perform reliably across real-world clinical data from multiple centres. By analysing thousands of cases under blinded conditions, we were able to demonstrate that PANProfiler Colorectal (MSI/MMR) delivers consistent performance comparable to standard laboratory testing, using only routine histology images."

The Human Impact of Instantaneous Insight

For the thousands of individuals diagnosed with colorectal cancer each year, the diagnostic journey is often fraught with uncertainty and stress. National audits and patient surveys have consistently shown that a significant number of patients either don't receive timely biomarker testing or face debilitating delays.

This waiting period is more than just an inconvenience; it can directly impact outcomes. During these weeks of uncertainty, clinical decisions may be made with incomplete information, potentially delaying access to the most effective treatments. The ability to shrink this timeline to minutes offers a profound benefit to patient care.

"Receiving an early cancer diagnosis can vastly improve a patient's experience and treatment outcomes," noted one senior pathologist familiar with the challenges in the field. Rapid molecular profiling allows oncologists to confidently and quickly map out a personalized treatment strategy, whether that involves surgery, chemotherapy, or initiating cutting-edge immunotherapy for which MSI/MMR status is a prerequisite.

By providing same-day insights, the AI tool empowers clinical teams to act decisively, triage patients for confirmatory testing where needed, and ensure that no time is wasted in the fight against cancer. This not only improves the clinical pathway but also provides immense relief to patients and their families by delivering clarity when it is needed most.

Paving the Way for Widespread Adoption

While the technology is impressive, its real-world impact hinges on regulatory approval, seamless integration, and clinical acceptance. Panakeia appears to be methodically addressing each of these hurdles. The PANProfiler Colorectal (MSI/MMR) software is already UKCA-marked, a conformity standard for products in Great Britain, and is being deployed in UK hospitals.

Significantly, the technology has been selected for the UK Medicines and Healthcare products Regulatory Agency's (MHRA) AI Airlock programme. This initiative is designed to help regulators and innovators work together to safely deploy cutting-edge AI medical devices, giving Panakeia a clear and collaborative path toward wider clinical use.

"This npj Digital Medicine publication validates our vision to make precision medicine accessible to patients and doctors globally," said Pahini Pandya, Founder and CEO of Panakeia. "This rigorous multi-site validation, combined with PANProfiler Colorectal (MSI/MMR) being UKCA-marked and deployed in hospitals, establishes it as a clinically validated solution that supports faster, more informed clinical decision-making."

This success in colorectal cancer is not an isolated achievement but a validation of the company's broader platform. A 2024 study in Nature Communications Medicine demonstrated the PANProfiler platform's ability to identify thousands of biomarkers across more than 30 different cancer types from routine images, showcasing the immense scalability of its 'biology-first' AI approach.

With a solid foundation of peer-reviewed evidence and active engagement with regulatory bodies, Panakeia is positioning its technology not as a niche tool, but as a foundational element for the future of diagnostics. Starting with deployment in the UK's National Health Service, the company is building a blueprint for healthcare systems worldwide, proving that AI can deliver on its promise to make precision medicine a reality for everyone, everywhere.